CrisprBits opens Research and Innovation Centre for CRISPR Gene Editing and Diagnostics in Bengaluru
BENGALURU, India, Jan. 16, 2025 /PRNewswire/ -- Bengaluru-based biotechnology startup, CrisprBits Private…
CrisprBits opens Research and Innovation Centre for CRISPR Gene Editing and Diagnostics in Bengaluru
BENGALURU, India, Jan. 16, 2025 /PRNewswire/ -- Bengaluru-based biotechnology startup, CrisprBits Private…
CrisprBits opens Research and Innovation Centre for CRISPR Gene Editing and Diagnostics in Bengaluru
BENGALURU, India, Jan. 16, 2025 /PRNewswire/ -- Bengaluru-based biotechnology startup, CrisprBits Private…
Breakthrough Gene Editing Technique Offers Hope for Stargardt Disease Patients
Researchers have developed a highly efficient gene editing therapy that could potentially…
Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreichs Ataxia
- SGT-212 is the only full-length frataxin replacement gene therapy candidate targeting…
Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for -Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
Treatment effects sustained through long-term follow-up of beyond 10 years in the…
US FDA Grants Orphan Drug Designation to EXG110, a Novel Gene Therapy for Fabry Disease
Company also Provides Updates on wet Age Related Macular Degeneration and Rare…
Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illuminas Updated Comprehensive Gene Panel Assay, TruSight Oncology 500 v2
Agreement will expand worldwide access and better position Myriad’s GIS as a…
Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression inTransthyretin (ATTR) Amyloidosis
Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence…
AlveoGene Receives Rare Pediatric Disease Designation (RPDD)from FDA for AVG-002, its Novel, Inhaled Gene Therapy forLethal Neonatal Surfactant Protein B (SP-B) Deficiency
Inherited SP-B deficiency is an ultra-rare monogenic cause of fatal respiratory distress…